C4x Discovery Investors - C4XD

C4x Discovery Investors - C4XD

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
C4x Discovery Holdings Plc C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change Price Change % Stock Price Last Trade
-0.50 -1.49% 33.00 16:35:04
Open Price Low Price High Price Close Price Previous Close
33.50 33.50 33.50 33.00 33.50
more quote information »
Industry Sector

Top Investor Posts

alloa2003: He said he was still focused on C4XD when I emailed the other day - he replied via his colleague. Doesn't look this way to me! Private shareholders are losing a fortune, recent institutional investors doing well and Clive making a huge name for himself AWAY from C4XD. Not good! No wonder there is no news, he has had his head turned!
alloa2003: Emailed C4XD today. Lets see if I get a reply:- I am an investor in C4XD and have been since the heady days when the shares were 50p+. During the last 12 months we have seen numerous fund raisings which have diluted private investors with the constant promise these funds will result in a stronger business. So far we have had next to no updates on existing treatments let alone any new ones, we have heard endless promises that partnership deals are in the offing but absolutely nothing to report. As a concept I believe strongly in this company but your PR skills are atrocious and the only winners lately have been the institutions taking on cheap stock at our expense. When can we expect any meaningful updates? When can we expect to see progress? I notice that Mr Dix is involved in a government Covid research project. At the moment it looks as though this is to the severe detriment of the company. If that is the case, you need to find a replacement asap to push the company along. A company that has raised a relatively huge amount of money lately which is disappearing each month with, so far, absolutely nothing to show for it. Unless results are forthcoming, I very much doubt the market will accept another fund raising even at the hugely dilutive levels which seem to have become the norm with C4XD.
amaretto1: They are in the market .. trying to sell the story to investors.Why not let the 14p shares go to private investors ....Who have gone through years of agony and pain.I'd buy back in at 14penceAnd hold next year ....
amaretto1: Very good post ...And very truePrivate investors are all left in the dark ... while the 14 p buyers are in the know !!WRONG
alloa2003: There are obviously things going on behind the scenes and those who invested in the recent fund raising will be aware of confidential information. However, it is about time we as long term shareholders were also made privy to what is going on. Yes, we know about commercial agreements etc but the fund raising in October last year was supposed to (among other things) strengthen the company's negotiating position with the big players. However, since then we have heard nothing about developments, new deals, etc which are obviously being discussed behind the scenes. We are expected to keep on taking a hit with dilution, which I dont mind if there is something at the end of it. The company needs to be more open with private investors and not just institutional investors. For the record I think the potential for this company is huge and the INDV money and another deal would probably push it towards being self financing going forward with huge cashflow.
the stigologist: Indivior Announces Participation in Upcoming Investor Conferences Slough, United Kingdom and Richmond, Virginia - November 10, 2020 - Indivior PLC (LON: INDV) today announced its participation in the following upcoming investor conferences: · November 16th, 8:00 AM US Eastern Time (ET): Stifel Virtual Healthcare Conference ( link ). · November 17th, 12:00 PM US Eastern Time (ET): Jefferies Virtual Global Healthcare Conference ( link ).
the stigologist: Commenting on the transaction, lead partner at Pinsent Masons Charles Waddell said: "We have enjoyed working with 4D for a number of years, they are at the cutting edge of live biotherapeutic products and this transaction is an important step in their future development and access to key to international markets. Given the number of European biotechs that covet a move to NASDAQ, and notwithstanding the complex financing structures of SPACs, this deal highlights that there is an alternative route to the US markets. It is therefore unlikely to be the last biotech we see looking at SPACs to access the deep pool of sophisticated investors in the US.
amaretto1: Agree .... i for one, would not have sold knowing this information,If this becomes the case, I'll be ringing Mr Dix and informing him of the price sensitive information being withheld to benefit institutional investors.And that's a big NO !!
the stigologist: Indivior to Announce 2020 Year-to-Date and Q3 Results October 29th Slough, UK, and Richmond, VA, 15 October 2020 - Indivior PLC (LON: INDV) today announced that it will release its 2020 year-to-date and third quarter results on Thursday, October 29th at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at www.indivior.com . Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 29th.
the stigologist: Investing isn’t an IQ test; it’s a test of character Analyzing two of the biggest stock-market winners of the past few decades, Mr. Housel says Netflix Inc. returned more than 35,000% between 2002 and 2018.  Yet, along the way, many investors quit; each stock spent at least 94% of the time trading below its previous all-time highs. Investors think of such volatility as a kind of “fine” for having made a mistake, says Mr. Housel. Instead, they should regard it as a “fee,” the unavoidable cost of participation. You never know how big the fee will be or when you will incur it, but patience can make it bearable. hTtps://www.wsj.com/articles/do-you-know-the-difference-between-being-rich-and-being-wealthy-11596808802.
ADVFN Advertorial
Your Recent History
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210124 18:58:45